We are single-minded in our pursuit of a cure for Glioblastoma Multiforme (GBM), and invite you to explore our Investor Relations page to understand the financial promise that aligns with our life-changing mission.

Nasdaq: CNSP View Details
0.15 USD
-0 (-0.15%)
27.2k Volume
CNS Pharmaceuticals September 10, 2024 3:30 PM EDT

New Releases

View All
HOUSTON, TX / ACCESSWIRE / September 4, 2024 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and...
Live webcast on Wednesday, August 28th at 3:20 PM ETHOUSTON, TX / ACCESSWIRE / August 27, 2024 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for...

Events

View All
Sep 09 2024 7:00 AM EDT

CNS Pharmaceuticals to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Sep 03 2024 12:00 AM EDT

BioMedWire Podcast

Aug 28 2024 10:56 PM EDT

LIVE! with Webull Corporate Connect: Biotech Investment Webinar

Stay Updated
At least one type of alert must be selected.
An email address is required.

Your email alerts were set.

The following alerts could not be set:

Resources

CNSP Investor Presentation PDF
01 August, 2024

Analyst Coverage

Jason McCarthy, PhD Maxim Group

CNS Pharmaceuticals, Inc. is followed by the analysts listed above. Please note that any opinions, estimates or forecasts regarding CNS Pharmaceuticals, Inc.'s performance made by these analysts are theirs alone and do not represent opinions, forecasts or predictions of CNS Pharmaceuticals, Inc. or its management. CNS Pharmaceuticals, Inc. does not by its reference above or distribution imply its endorsement of or concurrence with such information, conclusions or recommendations.

Company

Management Team View
SEC Filings View
Events and Presentations View
FAQ View
Contact IR View

CNS Pharmaceuticals a clinical-stage pharmaceutical company developing a pipeline of anti-cancer drug candidates for the treatment of primary and metastatic cancers of the brain and central nervous system malignancies. The Company’s lead drug candidate, Berubicin, is a novel anthracycline and the first anthracycline to appear to cross the blood-brain barrier. Berubicin is currently in development for the treatment of a number of serious brain and CNS oncology indications including glioblastoma multiforme (GBM), an aggressive and incurable form of brain cancer.

Additionally, the Company is advancing the development of its WP1244 drug technology, which utilizes anthracycline and distamycin-based scaffolds to create small molecule agents and is believed to be 500x more potent than daunorubicin in inhibiting tumor cell proliferation. Preclinical studies of WP1244 demonstrated high uptake in the brain with antitumor activity. CNS Pharmaceuticals is evaluating the use of WP1244 in the treatment of brain cancers, pancreatic, ovarian, and lymphomas.